Everest Medicines First Half 2023 Earnings: CN¥1.40 loss per share (vs CN¥2.26 loss in 1H 2022)

Everest Medicines (HKG:1952) First Half 2023 Results

Key Financial Results

• Net loss: CN¥423.6m (loss narrowed by 37% from 1H 2022).
• CN¥1.40 loss per share (improved from CN¥2.26 loss in 1H 2022).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Everest Medicines Earnings Insights

Looking ahead, revenue is forecast to grow 50% p.a. on average during the next 3 years, compared to a 35% growth forecast for the Biotechs industry in Hong Kong.

Performance of the Hong Kong Biotechs industry.

The company's shares are down 13% from a week ago.

Risk Analysis

It's necessary to consider the ever-present spectre of investment risk. We've identified 5 warning signs with Everest Medicines (at least 2 which are concerning), and understanding these should be part of your investment process.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.